Share
jes_cover

Sexual Development Disorders May Be More Common Than Previously Thought

Ambiguous genitalia in newborns may be more common than previously thought, according to a study published in the Endocrine Society’s Journal of the Endocrine Society. Disorders of sexual development (DSD) are a group of conditions that include anomalies of the sex chromosomes, the gonads, the reproductive ducts and the genitalia. Ambiguous genitalia is when a...
Share

Advocacy in Action: EDCs in Europe, E/M Codes, and More

capitolhill Here is a quick run down of major issues being discussed by policymakers from an endocrine perspective and the Society’s current advocacy work.  What’s Happening in Washington The Endocrine Society is hard at work advocating Congress to increase funding for NIH in FY2020 and reauthorize the Special Diabetes Program before September 30. It is critical...
Share

Endocrine Society Commends European Parliament’s EDC Resolution

The Endocrine Society praised the European Parliament’s resolution calling for greater European Union action to regulate endocrine-disrupting chemicals (EDCs) that pose a serious threat to the health of current and future generations. The resolution was adopted Thursday by an overwhelming cross-party majority during the final voting session of the current Parliament’s term and affirms the...
Share

Gaining Ground, Losing Weight

According to recent studies published in The Journal of Clinical Endocrinology & Metabolism, researchers are getting a better understanding of obesity and the continuing efforts to combat it. While the bad news is that there are a variety of side effects, the good news is that not all of the side effects are negative. With...
Share

FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk of Fracture

The U.S. Food and Drug Administration has approved romosozumab-aqqg to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. The drug will be marketed...